ReviewCells2022
Myasthenia Gravis: An Acquired Interferonopathy?
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- On the road to blood biomarkers in myasthenia gravis (MG): Beyond clinical scales.Journal of neuromuscular diseases · 2026Review
- Monocyte-macrophage SAMHD1 alleviates EAMG by modulating the cGAS-STING pathway.Journal of neuroinflammation · 2026Article
- Platelet activation plays a pro-inflammatory role in myasthenia gravis.Nature communications · 2025Article
- Immunological Targets in Generalized Myasthenia Gravis Treatment: Where Are We Going Now?Brain sciences · 2025Review
- Article
- Thymic hyperplasia in myasthenia gravis: a narrative review.Mediastinum (Hong Kong, China) · 2025Review
- Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects.Signal transduction and targeted therapy · 2024Review
- Review
- Decoding myasthenia gravis: advanced diagnosis with infrared spectroscopy and machine learning.Scientific reports · 2024Article
- Clinical features of thymoma with and without myasthenia gravis.Pakistan journal of medical sciences · 2024Article
- Astragaloside IV protects against autoimmune myasthenia gravis in rats via regulation of mitophagy and apoptosis.Molecular medicine reports · 2024Article
- Myasthenia gravis: the future is here.The Journal of clinical investigation · 2024Review
- Nanodrug Delivery Systems for Myasthenia Gravis: Advances and Perspectives.Pharmaceutics · 2024Review
- Physiological and pathological roles of the thymus and value of thymectomy in myasthenia gravis: a narrative review.Mediastinum (Hong Kong, China) · 2024Review
- The role of interferon in the thymus.Current opinion in immunology · 2023Review
- Plasma Myokine Profiles in Patients With AChR- and MuSK-Ab-Positive Myasthenia Gravis.Journal of clinical neurology (Seoul, Korea) · 2023Article
- Transcriptional landscape of myasthenia gravis revealed by weighted gene coexpression network analysis.Frontiers in genetics · 2023Article
- Single-cell transcriptomics and network pharmacology reveal therapeutic targets of Jianpi Yiqi Bugan Yishen decoction in immune cell subsets of children with myasthenia gravis.Translational pediatrics · 2022Article
- Is Myasthenia Gravis a Real Complication of the COVID-19 Vaccine? A Case Report-Based Systematic Review.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) is a rare autoimmune disease mediated by antibodies against components of the neuromuscular junction, particularly the acetylcholine receptor (AChR). The thymus plays a primary role in AChR-MG patients. In early-onset AChR-MG and thymoma-associated MG, an interferon type I (IFN-I) signature is clearly detected in the thymus. The origin of this chronic IFN-I expression in the thymus is not yet defined. IFN-I subtypes are normally produced in response to viral infection. However, genetic diseases called interferonopathies are associated with an aberrant chronic production of IFN-I defined as sterile inflammation. Some systemic autoimmune diseases also share common features with interferonopathies. This review aims to analyze the pathogenic role of IFN-I in these diseases as compared to AChR-MG in order to determine if AChR-MG could be an acquired interferonopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.